Saxenda
Payments companies reported to CMS as associated with Saxenda. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Saxenda, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Saxenda
These are the largest totals companies reported as associated with Saxenda. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Pam Taub | La Jolla, CA | Cardiovascular Disease | $62,157.52 |
| Carlos Mena-Hurtado | New Haven, CT | Cardiovascular Disease | $36,110.00 |
| Francisco Lopez-Jimenez | Rochester, MN | Cardiovascular Disease | $25,905.00 |
| Michael Nanna | New Haven, CT | Interventional Cardiology | $23,550.00 |
| Claudia Fox | Minneapolis, MN | Pediatrics | $16,467.39 |
| Angela Fitch | Boston, MA | Obesity Medicine (Internal Medicine) | $13,489.76 |
| Wajahat Mehal | West Haven, CT | Gastroenterology (Internal Medicine) | $13,067.96 |
| Holly Lofton | New York, NY | Obesity Medicine (Preventive Medicine) | $12,513.83 |
| Michael Kobernick | Warren, MI | Emergency Medicine | $8,988.48 |
| Sara Tabtabai | Hartford, CT | Advanced Heart Failure and Transplant Cardiology | $5,887.50 |
Prescribed Saxenda?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.